Journal article icon

Journal article

Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting

Abstract:

Relapsed or refractory classical Hodgkin lymphoma (cHL) is associated with a poor outcome when standard chemotherapy fails. Brentuximab vedotin (BV) is an anti-CD30 monoclonal antibody-drug conjugate licensed for use at relapse after autologous stem cell transplant (ASCT) or following two prior therapies in those unsuitable for ASCT. There are limited data assessing the ability of BV to enable curative SCT. We performed a UK-wide retrospective study of 99 SCT-naïve relapsed/refractory cHL. Al...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.1111/bjh.14898

Authors


More by this author
Department:
Oxford University Hospitals NHS Foundation Trust, Department of Haematology
Role:
Author
Expand authors...
Julian Starmer-Smith lymphoma fund More from this funder
National Institute for Health Research Biomedical Research Centre Programme More from this funder
Publisher:
Wiley Publisher's website
Journal:
British Journal of Haematology Journal website
Volume:
179
Issue:
3
Pages:
471-479
Publication date:
2017-08-31
Acceptance date:
2017-07-18
DOI:
EISSN:
1365-2141
ISSN:
0007-1048
Pubs id:
pubs:725854
URN:
uri:db8a45c6-e6e1-4263-aba2-c8c8d3b8abc2
UUID:
uuid:db8a45c6-e6e1-4263-aba2-c8c8d3b8abc2
Local pid:
pubs:725854
Language:
English
Keywords:

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP